




Milestone
PHARMACEUTICALS



Milestone (Nasdaq: MIST)

Corporate Highlights

- ▶ Founded in 2005 in Quebec, Canada (HQ)
- ▶ US subsidiary in Charlotte, North Carolina
- ▶ Approximately 50 team members across North America
- ▶ Potentially first new drug therapy for PSVT in >25 years
- ▶ New chemical entity with proprietary IP
- ▶ Pipeline opportunities beyond the lead indication (e.g., Afib-RVR)
- ▶ Potentially paradigm-changing approach for patients to self-manage their episodes



To learn more about our clinical pipeline and read recent publications, visit milestonepharma.com




Phase 3 Cardiovascular Company



Targeting Large Areas of Unmet Need

- ▶ PSVT
- ▶ AFib-RVR
- ▶ Additional pipeline opportunities



Potentially Paradigm- Changing Approach

- ▶ Etripamil: investigational novel calcium channel blocker (IP protection until 2036)
- ▶ Shift from the ED to patient self-management



Recent Events Position Us for Future Success

- ▶ Phase 3 RAPID study complete and primary results are being presented at AHA
- ▶ Plan to submit US New Drug Application (NDA) mid 2023

We're with you every beat of the way



Milestone
PHARMACEUTICALS